Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2...

{
  "signal_id": "7de68455-db87-84f1-75d8-5ec8bfef2f09",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-16T14:31:00+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/sjogrens-syndrome-market-to-witness-sustained-growth-during-the-forecast-period-20262036-due-to-the-development-of-targeted-immunotherapies-fcrn-inhibitors-tyk2-inhibitors-and-cell-therapies--delveinsight-302880059.html",
    "title": "Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight",
    "excerpt": "The Sjögren's syndrome market is undergoing a notable transformation, moving beyond traditional symptomatic management toward targeted immunomodulatory therapies. Emerging candidates, including Telitacicept (Vor Biopharma), Dazodalibep (Amgen), Nipocalimab (Johnson & Johnson), Deucravacitinib (SOTYKTU; Bristol-Myers Squibb), and others, are drawing considerable attention for their potential to target underlying disease pathways, modulate autoimmune activity, and restore or improve glandular function. LAS VEGAS , Sept. 16, 2026 /PRNewswire/ -- Recently published Sjogren's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Sjogren's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Sjogren's Syndrome Market Summary Discover Sjogren's syndrome clinical trial 2026 update press release @ https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size Key Factors Driving the Growth of the Sjogren's Syndrome Market Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that Ianalumab, with its dual mechanism, positive Phase III results, and FDA Breakthrough Therapy designation, has the potential to become...",
    "product": "Dazodalibep",
    "summary": "Amgen is developing Dazodalibep, an investigational biologic targeting the CD40-CD40L pathway for Sjögren's disease.",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS1196378/logo-png.jpg?id=OA2951961&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Dazodalibep",
      "full_text": "Amgen's Dazodalibep is an investigational biologic",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical",
      "future_tech"
    ],
    "published_at": "2026-09-16T14:31:00Z",
    "article_sentence": "Amgen's Dazodalibep is an investigational biologic targeting the CD40-CD40L pathway, a critical mediator of immune activation and autoimmune inflammation."
  }
}

curl https://signals.autobound.ai/v1/signals/7de68455-db87-84f1-75d8-5ec8bfef2f09 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'